GlobeNewswire Inc.··Nervgen Pharma Corp.NervGen Pharma Raises $60M via Public Offering to Advance Spinal Cord Therapy
NervGen Pharma prices $60M public offering of 24M shares at $2.50 each to fund NVG-291 clinical development through 2026.
NGENwarrantspublic offering